Top

Published in:

01-06-2004 | Original Paper

Inhibition of melanoma metastases by fenofibrate

Authors: Maja Grabacka, Wojciech Placha, Przemyslaw M. Plonka, Stanislawa Pajak, Krystyna Urbanska, Piotr Laidler, Andrzej Slominski

Published in: Archives of Dermatological Research | Issue 2/2004

Abstract

The effect of fenofibrate, a ligand of peroxisome proliferator-activated receptor (PPAR) α, on the growth and metastatic potential of Bomirski hamster melanoma s.c. tumors, pigmented line (BHM Ma) was investigated in vivo. RT-PCR and Western-blot analyses revealed the presence of mRNA and protein of PPAR α in BHM Ma cells. The animals treated orally with fenofibrate developed significantly fewer metastatic foci in the lungs, as compared to the control group; however, primary tumor growth remained unaltered. This observation is interesting in respect of the potential use of fenofibrate in melanoma chemoprevention.

Aranega A, Gonzalez FJ, Aranega AE, Muros MA, Fernandez JE, Velez C, Prados J, Alvarez L (1991) Effects of fibric acid derivatives on accumulation of actin in myocardiocytes. Int J Cardiol 33:47–54PubMedCrossRef

Aranega AE, Velez MC, Gonzalez FJ, Melguizo C, Prados JC, Aranega A (1995) Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives. Eur J Morphol 33:421–431PubMed

Blane GF (1989) Review of European clinical experience with fenofibrate. Cardiology 76 [Suppl 1]:1–10

Bomirski A, Slominski A, Bigda J (1988) The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev 7:95–118PubMed

Cardones AR, Murakami, T, Hwang ST (2003) CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta (1) integrin. Cancer Res 63:6751–6757PubMed

Chinetti G, Fruchart JC, Staels B (2001) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 90 [Suppl 3]:125–132

Chomczynski P, Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162:156–159PubMedCrossRef

Dellavalle RP, Nicholas MK, Schilling LM (2003) Melanoma chemoprevention: a role for statins and fibrates? Am J Ther 10:203–210PubMed

Demierre MF, Nathanson (2003) Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 21:158–165PubMedCrossRef

10.

Downs JR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622PubMedCrossRef

11.

Elstner E, Muller C, Koshizuka K, Williamson E, Park D, Asou H, Shintaku P, Said JW., Heber D, Koeffler HP (1998) Ligands for peroxisome proliferator-activated receptor α and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 95:8806–8811PubMedCrossRef

12.

Engebraaten O, Bjerkvig R, Berens ME (1991) Effects of alkyl-lysophospholipid on glioblastoma cell invasion into fetal rat brain tissue in vitro. Cancer Res 51:1713–1719PubMed

13.

Escher P, Wahli W (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448:121–138PubMed

14.

Farina HG, Bublik DR, Alonso DF, Gomez DE (2002) Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 19:551–559PubMedCrossRef

15.

Frishman WH, Rapier RC (1989) Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am 73:437–448PubMed

16.

Gonzalez F, Peters JM, Cattley RC (1990) Review: mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor α. J Natl Cancer Inst 90:1702–1709

17.

Guan RJ, Ford JL, Fu YN, Li YZ, Shaw LM, Pardee AB (2000) Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 60:749–755PubMed

18.

Hyrc K, Kapiszewska M, Cieszka K (1985) Differences in the electrophoretic mobilities of pigmented and non-pigmented melanoma cells. In: Schutt W, Klinkmann H (eds) Cell electrophoresis. Walter de Gruyter, Berlin New York, pp 451–457

19.

Jakobisiak M, Golab J (2003) Potential antitumor effects of statins (review). Int J Oncol 23:1055–1069PubMed

20.

Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V, Katoh A (1993) Metastasis of B16 F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13:314–324PubMed

21.

Keelan JA, Sato T A, Marvin KW, Lander J, Gilmour RS, Mitchell M. (1999) 15-Deoxy-Δ12,14-prostaglandin J2, a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 262:579–585PubMedCrossRef

22.

Kier AB, Parker MT, Schroeder F (1988) Local and metastatic tumor growth and membrane properties of LM fibroblasts in athymic (nude) mice. Biochim Biophys Acta 938:434–446PubMed

23.

Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans DM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771–774PubMedCrossRef

24.

Kort WJ, Hulsmann WC, Stehman TE (1989) Modulation of metastatic ability by inhibition of cholesterol synthesis. Clin Exp Metastasis 7:517–523PubMed

25.

Kroetz D, Yook P, Costet P, Pineau T (1998) Peroxisome proliferator-activated receptor α (PPAR α) controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 273:31581–31589PubMedCrossRef

26.

Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680–685PubMedCrossRef

27.

Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150:179–185PubMedCrossRef

28.

Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB (1991) Crystallographic analysis of interaction of the glucocorticoid receptor with DNA. Nature 352:497–505PubMedCrossRef

29.

Lukiewicz S, Pilas B, Nowicka J, Cieszka K, Gurbiel R (1981) Molecular and cellular basis of different radiosensitivity in pigmented and nonpigmented hamster melanoma cells. In: Seiji H (ed) Pigment cell. Phenotypic expression in pigment cells. Proceedings of the XIth International Pigment Cell Conference, Sendai, Japan. University of Tokyo Press, Tokyo, pp 23–29

30.

Martin G, Duez H, Blanquart C, BerezowskiV, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B (2001) Statin-induced inhibition of the Rho signalling pathway activates PPAR α and induces HDL-apoAI. J Clin Invest 107:1423–1432PubMedCrossRef

31.

McIntosh TJ (1978) The effect of cholesterol on the structure of phosphatidylcholine bilayers. Biochim Biophys Acta 513:43–58PubMed

32.

Mossner R, Schulz U, Kruger U, Middel P, Shinner S, Fuzesi L, Neumann C, Reich K (2002) Agonists of peroxisome proliferator-activated receptors γ inhibit cell growth in malignant melanoma. J Invest Dermatol 119:576–582PubMedCrossRef

33.

Neitzel LT, Neitzel CD, Magee KL, Malafe MP (1999) Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 6:70–74PubMedCrossRef

34.

Nyguist DA, Watanabe I, Melnykovych G (1992) Alkyllysophospholipid influenced melanoma cell morphology is associated with decreased attachment to basement membrane. Ukr Biokhim Zh 64:76–85PubMed

35.

Pineau T, Hudgins RW, Liu L, Chen L, Sher T, Gonzalez FJ, Samid D (1996) Activation of human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52:659–667PubMedCrossRef

36.

Placha W, Gil D, Dembinska-Kiec A, Laidler P (2003) The effect of PPAR γ ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13:447–456PubMed

37.

Rival Y, Benéteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau J-F, Junquéro D, Colpaert FC, Delhon A (2002) PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143–151PubMedCrossRef

38.

Rog T, Pasenkiewicz-Gierula M (2001) Cholesterol effects on the phospholipid condensation and packing in the bilayer: a molecular simulation study. FEBS Lett 502:68–71PubMed

39.

Romanowska-Dixon B, Urbanska K, Elas M, Pajak S, Zygulska-Mach H, Miodonski A (2001) Angiomorphology of the pigmented Bomirski melanoma growing in hamster eye. Ann Anat 183:559–565PubMed

40.

Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farnesyltransferase inhibitors: a strategic target for anticancer therapeutic development. J Clin Oncol 17:3631–3652PubMed

41.

Rubins HB, Robins SJ, Collins CL, Anderson JW, Elam MB, Faas FH, Linares EJ, Schaeffer EJ, Schechtman G, Wilt TJ, Wittes J (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study. N Engl J Med 341:410–418PubMedCrossRef

42.

Schreck R (1936) Further quantitative methods for the study of transplantable tumors. The growth of R39 sarcoma and Brown–Pierce carcinomas. Am J Cancer 28:345–351

43.

Schroeder F, Gardiner JM (1984) Membrane lipids and enzymes of high- and low-metastatic B16 melanoma variants. Cancer Res 44:3262–3269PubMed

44.

Scislowski PWD, Slominski A, Bomirski A, Zydowo B (1985) Metabolic characterization of three hamster melanoma variants. Neoplasma 32:593–598PubMed

45.

Sherbet GV (1989) Membrane fluidity and cancer metastasis. Exp Cell Biol 57:198–205PubMed

46.

Singh RP, Kumar R, Kapur N (2003) Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis. J Environ Pathol Toxicol Oncol 22:75–92PubMed

47.

Siperstein MD (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 25:1462–1468PubMed

48.

Siperstein MD, Fagan VM (1964) Deletion of the cholesterol-negative feedback system in liver tumors. Cancer Res 24:1108–1115PubMed

49.

Slominski A, Paus R (1993) Bomirski melanomas: a versatile and powerful model for pigment cell and melanoma research (review). Int J Oncol 2:221–228

50.

Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC (2001) Malignant melanoma. An update. Arch Pathol Lab Med 125:1295–1306PubMed

51.

Storme G, Berdel WE, Van Blittersvijk WJ, Bruynel EA, De Bruyne GK, Mareel MM (1985) Antiinvasive effect of racemic 1-O octadecyl-2-O-methylglycero-3- phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res 45:351–357PubMed

52.

Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, Mishal Z, Soria J, Li H, Soria C (2003) Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60:810–819PubMed

53.

Vereb G, Matko J, Vamosi G, Ibrahim SM, Magyar E, Varga S, Szollosi J, Jenei A, Gaspar R Jr, Waldmann TA, Damjanovich S (2000) Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. Proc Natl Acad Sci U S A 97:6013–6018PubMedCrossRef

54.

Wulfert E, Boissard G, Legendre C, Baron C (1981) Inhibition of membrane-bound hepatic 3 hydroxy-3 methyl glutaryl CoA reductase as the consequence of altered membrane fluidity. Artery 9:120–131PubMed

Title: Inhibition of melanoma metastases by fenofibrate
Authors: Maja Grabacka
Wojciech Placha
Przemyslaw M. Plonka
Stanislawa Pajak
Krystyna Urbanska
Piotr Laidler
Andrzej Slominski
Publication date: 01-06-2004
Publisher: Springer-Verlag
Published in: Archives of Dermatological Research / Issue 2/2004
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-004-0479-y

At a glance: The STEP trials

Springer Medicine

Inhibition of melanoma metastases by fenofibrate

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2004

Immunophenotype and possible origin of nevi with phenotypical heterogeneity

A time of change

Cyclic AMP differentially regulates cell proliferation of normal human keratinocytes through ERK activation depending on the expression pattern of B-Raf

Message from the new Editor-in-Chief

A study of cytokeratin profiles in localized cutaneous amyloids

Inhibitors of cysteine cathepsin and calpain do not prevent ultraviolet-B-induced apoptosis in human keratinocytes and HeLa cells